JP2019063086A - 薬剤コート層およびその形成方法 - Google Patents
薬剤コート層およびその形成方法 Download PDFInfo
- Publication number
- JP2019063086A JP2019063086A JP2017189565A JP2017189565A JP2019063086A JP 2019063086 A JP2019063086 A JP 2019063086A JP 2017189565 A JP2017189565 A JP 2017189565A JP 2017189565 A JP2017189565 A JP 2017189565A JP 2019063086 A JP2019063086 A JP 2019063086A
- Authority
- JP
- Japan
- Prior art keywords
- balloon
- drug
- solvent
- layer
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 204
- 229940079593 drug Drugs 0.000 title claims abstract description 201
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000011247 coating layer Substances 0.000 title claims abstract description 10
- 239000010410 layer Substances 0.000 claims abstract description 215
- 239000013078 crystal Substances 0.000 claims abstract description 169
- 239000002904 solvent Substances 0.000 claims description 143
- 239000011248 coating agent Substances 0.000 claims description 59
- 238000000576 coating method Methods 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 229930012538 Paclitaxel Natural products 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 7
- 229960003668 docetaxel Drugs 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 229960005167 everolimus Drugs 0.000 claims description 7
- 230000002688 persistence Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 35
- 239000000654 additive Substances 0.000 description 31
- 230000007246 mechanism Effects 0.000 description 29
- 239000007788 liquid Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 230000000996 additive effect Effects 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 150000003384 small molecules Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- -1 polyethylene Polymers 0.000 description 11
- 239000004952 Polyamide Substances 0.000 description 9
- 229920002647 polyamide Polymers 0.000 description 9
- 208000031481 Pathologic Constriction Diseases 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 208000037804 stenosis Diseases 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920002292 Nylon 6 Polymers 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920000571 Nylon 11 Polymers 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000806 elastomer Substances 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 3
- 229920000299 Nylon 12 Polymers 0.000 description 3
- 229920002302 Nylon 6,6 Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000009474 immediate action Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 0 C=Cc1ccc(C2)*2c1 Chemical compound C=Cc1ccc(C2)*2c1 0.000 description 2
- 229920000305 Nylon 6,10 Polymers 0.000 description 2
- 229920000572 Nylon 6/12 Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000011295 pitch Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000005944 tissue migration Effects 0.000 description 2
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920012753 Ethylene Ionomers Polymers 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003189 Nylon 4,6 Polymers 0.000 description 1
- 229920000577 Nylon 6/66 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- TZYHIGCKINZLPD-UHFFFAOYSA-N azepan-2-one;hexane-1,6-diamine;hexanedioic acid Chemical compound NCCCCCCN.O=C1CCCCCN1.OC(=O)CCCCC(O)=O TZYHIGCKINZLPD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- ZMUCVNSKULGPQG-UHFFFAOYSA-N dodecanedioic acid;hexane-1,6-diamine Chemical compound NCCCCCCN.OC(=O)CCCCCCCCCCC(O)=O ZMUCVNSKULGPQG-UHFFFAOYSA-N 0.000 description 1
- GKCXXDSWWDWUHS-BYPYZUCNSA-N ethyl (2s)-2-amino-3-hydroxypropanoate Chemical compound CCOC(=O)[C@@H](N)CO GKCXXDSWWDWUHS-BYPYZUCNSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical group FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 239000002698 neuron blocking agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
<第1実施形態>
<第2実施形態>
30 バルーン
32 羽根部
40、140 薬剤コート層
41、141 結晶層
42 長尺体
43 添加剤
51、142 アモルファス層
Claims (10)
- バルーンの表面に設けられる薬剤コート層であって、
前記バルーンの表面に設けられる水不溶性の薬剤結晶を含む結晶層と、
前記バルーンの表面の前記結晶層と異なる位置に所定の範囲で設けられるとともに、アモルファス型の水不溶性薬剤を含むアモルファス層と、を有する薬剤コート層。 - 前記アモルファス層は、前記結晶層に囲まれて点状または線状の範囲に設けられる請求項1に記載の薬剤コート層。
- 前記バルーンは、径方向の外側へ突出するとともに前記バルーンの周方向に沿って折り畳まれる複数の羽根部を有し、
前記結晶層は、前記羽根部が折り畳まれる前記バルーンの外部へ露出する位置に設けられ、
前記アモルファス層は、前記羽根部が折り畳まれることで重なって対向する前記バルーンの表面に設けられる請求項1または2に記載の薬剤コート層。 - 前記結晶層は、長軸を有する水不溶性薬剤の結晶である複数の長尺体を有する請求項1〜3のいずれか1項に記載の薬剤コート層。
- 前記水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、およびエベロリムスからなる群から選択される少なくとも1つを含有する請求項1〜4のいずれか1項に記載の薬剤コート層。
- バルーンの表面に設けられる薬剤コート層の形成方法であって、
水不溶性薬剤および溶媒を含むコーティング溶液を前記バルーンの表面に供給して乾燥させて薬剤結晶を含む結晶層を前記バルーンの表面に形成するステップと、
前記薬剤結晶を溶解可能な溶媒を前記結晶層へ部分的に供給して前記薬剤結晶を部分的に溶解させるステップと、
前記薬剤結晶を溶解させた溶媒を乾燥させてアモルファス型の薬剤を含むアモルファス層を形成するステップと、を有する薬剤コート層の形成方法。 - 前記薬剤結晶を溶解させるステップにおいて、前記薬剤結晶を溶解可能な溶媒を前記結晶層へ点状または線状の範囲に供給する請求項6に記載の薬剤コート層の形成方法。
- 前記薬剤結晶を溶解させるステップの前に、
前記結晶層を形成した前記バルーンに径方向の外側へ突出する羽根部を形成するステップと、
前記羽根部を前記バルーンの周方向に沿って折り畳むステップと、を有し、
前記薬剤結晶を溶解させるステップにおいて、前記羽根部が折り畳まれることで重なる前記バルーンの隙間に、前記薬剤結晶を溶解可能な溶媒を供給する請求項6または7に記載の薬剤コート層の形成方法。 - 前記結晶層は、長軸を有する水不溶性薬剤の結晶である複数の長尺体を有する請求項6〜8のいずれか1項に記載の薬剤コート層の形成方法。
- 前記水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、およびエベロリムスからなる群から選択される少なくとも1つを含有する請求項6〜9のいずれか1項に記載の薬剤コート層の形成方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017189565A JP6942593B2 (ja) | 2017-09-29 | 2017-09-29 | 薬剤コート層およびその形成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017189565A JP6942593B2 (ja) | 2017-09-29 | 2017-09-29 | 薬剤コート層およびその形成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019063086A true JP2019063086A (ja) | 2019-04-25 |
JP6942593B2 JP6942593B2 (ja) | 2021-09-29 |
Family
ID=66337288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017189565A Active JP6942593B2 (ja) | 2017-09-29 | 2017-09-29 | 薬剤コート層およびその形成方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6942593B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712672A (zh) * | 2022-04-14 | 2022-07-08 | 四川大学华西医院 | 一种载药球囊导管 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009240783A (ja) * | 2008-03-31 | 2009-10-22 | Cordis Corp | 治療薬の液体調合物を用いる局所送達および/または所与の領域に亘る送達のための装置 |
JP2011525849A (ja) * | 2008-06-25 | 2011-09-29 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 治療剤を含む医療機器 |
US20130053947A1 (en) * | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical Device with Crystalline Drug Coating |
WO2017164280A1 (ja) * | 2016-03-23 | 2017-09-28 | テルモ株式会社 | バルーンカテーテル及びその製造方法並びに処置方法 |
-
2017
- 2017-09-29 JP JP2017189565A patent/JP6942593B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009240783A (ja) * | 2008-03-31 | 2009-10-22 | Cordis Corp | 治療薬の液体調合物を用いる局所送達および/または所与の領域に亘る送達のための装置 |
JP2011525849A (ja) * | 2008-06-25 | 2011-09-29 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 治療剤を含む医療機器 |
US20130053947A1 (en) * | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical Device with Crystalline Drug Coating |
WO2017164280A1 (ja) * | 2016-03-23 | 2017-09-28 | テルモ株式会社 | バルーンカテーテル及びその製造方法並びに処置方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712672A (zh) * | 2022-04-14 | 2022-07-08 | 四川大学华西医院 | 一种载药球囊导管 |
CN114712672B (zh) * | 2022-04-14 | 2023-07-18 | 四川大学华西医院 | 一种载药球囊导管 |
Also Published As
Publication number | Publication date |
---|---|
JP6942593B2 (ja) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108883257B (zh) | 球囊导管及其制造方法以及处置方法 | |
JP6832339B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP6754423B2 (ja) | バルーンカテーテル及びその製造方法 | |
JP2017169740A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP6668131B2 (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
CN111032103B (zh) | 药物涂层的形成方法及形成装置 | |
JP7073337B2 (ja) | バルーンカテーテルの製造方法 | |
JP2019063086A (ja) | 薬剤コート層およびその形成方法 | |
JP7246311B2 (ja) | 薬剤コート層およびその形成方法 | |
JP6697917B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2017169738A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP6914612B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JPWO2018169051A1 (ja) | バルーンコーティング方法 | |
JP6961442B2 (ja) | 薬剤コート層の形成方法 | |
JP7118222B2 (ja) | バルーンカテーテルおよびその製造方法 | |
JP6704273B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP6832340B2 (ja) | バルーンカテーテルおよびその製造方法 | |
JP6697916B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2019063087A (ja) | 薬剤コート層の形成方法および形成装置 | |
JP2017169733A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2017169742A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2018153282A (ja) | バルーンコーティング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200603 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210621 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210908 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6942593 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |